Business
Voyageur Pharmaceuticals Ltd. Completes Medical Imaging CT Contrast Agent Production Testing and Begins Production Scale-up of SmoothX (TM)
(TheNewswire) Calgary, Alberta – TheNewswire - November 28, 2022 :...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Completes Medical Imaging CT Contrast Agent Production Testing and Begins Production Scale-up of SmoothX (TM)\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta –\n \n \n TheNewswire -\n \n \n November 28, 2022\n \n \n :\nVoyageur Pharmaceuticals Ltd.\n \n \n (TSXV:VM)\n \n \n (\n \n \n OTC\n \n \n :VYYRF) (the \"Company\" or\n\"Voyageur\") announces completion of the production test\nbatch of its SmoothX™ barium sulfate CT contrast media oral\nsuspension for the CT imaging market in Canada.  This development\nrepresents a significant transition for Voyageur from the development\nphase to the production phase, where the focus will change to scaling\nup to commercially viable volumes of SmoothX to supply the Canadian\nimaging market. Management estimates that t\n \n \n \n hese two milestones will likely speed up first commercial\nsales in Canada and the FDA filing for approval in the\nUS.\n \n \n \n \n \n \n Voyageur continues to advance the\ndevelopment and testing of four additional Health Canada approved\nimaging products for sales in the Canadian radiology market. Voyageur\ncurrently holds Health Canada approval licenses for five barium\ncontrast media products.\n \n \n \n \n \n \n Brent Willis,\nVoyageur\n \n \n \n \n ’\n \n \n \n \n s CEO stated:\n“The completion of production testing for SmoothX and the scaleup to\ncommercial quantities to launch sales in Canada is an important\nmilestone for the Company. It also marks a key point in our journey to\ncreate a fully integrated Canadian supply chain for barium contrast\nmedia. It also supports Canada\n \n \n \n \n ’\n \n \n \n \n s national\nstrategy of de-coupling from China for the supply of critical minerals\nand critical pharmaceutical production. Basing our production testing\non FDA protocols will advance our preparation for a generic drug\nsubmission to the FDA for the approval of SmoothX for gastrointestinal\nimaging. We have been engaged with the FDA on the path to approval for\nSmoothX since earlier this year and are now formally in contact with\nthe FDA\n \n \n \n \n ’\n \n \n \n \n s Office of\nGeneric Drugs regarding the specific requirements of approval for\nSmoothX.”\n \n \n \n \n \n In preparation for a generic drug submis...